Abstract
A significant minority of chronic myeloid leukaemia patients eventually develop resistance to imatinib, often as a result of point mutations within the BCR-ABL kinase domain. Second-line tyrosine kinase inhibitors (TKIs)...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have